Continuous infusion intermediate-dose cytarabine, mitoxantrone, plus etoposide for refractory or early relapsed acute myelogenous leukemia

Lee, Je-Hwan; Choi, Seong-Jun; Lee, Jung-Hee; Lee, Young-Shin; Seol, Miee; Ryu, Seong-Gil; Jang, Seongsoo; Park, Chan-Jeoung; Chi, Hyun-Sook; Lee, Jung-Shin; Kim, Woo-Kun; Lee, Kyoo-Hyung

doi:10.1016/j.leukres.2005.06.013

« Previous Next »Leukemia Research
Volume 30, Issue 2 , Pages 204-210, February 2006

Continuous infusion intermediate-dose cytarabine, mitoxantrone, plus etoposide for refractory or early relapsed acute myelogenous leukemia

Je-Hwan Lee
- Departments of Internal Medicine, Asan Medical Center, University of Ulsan, College of Medicine, 388-1 Pungnap-2dong, Songpa-gu, Seoul 138-736, South Korea
- Corresponding author. Tel.: +82 2 3010 3218; fax: +82 2 3010 6961.
Seong-Jun Choi
- Departments of Internal Medicine, Asan Medical Center, University of Ulsan, College of Medicine, 388-1 Pungnap-2dong, Songpa-gu, Seoul 138-736, South Korea
Jung-Hee Lee
- Departments of Internal Medicine, Asan Medical Center, University of Ulsan, College of Medicine, 388-1 Pungnap-2dong, Songpa-gu, Seoul 138-736, South Korea
Young-Shin Lee
- Departments of Internal Medicine, Asan Medical Center, University of Ulsan, College of Medicine, 388-1 Pungnap-2dong, Songpa-gu, Seoul 138-736, South Korea
Miee Seol
- Departments of Internal Medicine, Asan Medical Center, University of Ulsan, College of Medicine, 388-1 Pungnap-2dong, Songpa-gu, Seoul 138-736, South Korea
Seong-Gil Ryu
- Departments of Internal Medicine, Asan Medical Center, University of Ulsan, College of Medicine, 388-1 Pungnap-2dong, Songpa-gu, Seoul 138-736, South Korea
Seongsoo Jang
- Departments of Laboratory Medicine, Asan Medical Center, University of Ulsan, College of Medicine, Seoul, South Korea
Chan-Jeoung Park
- Departments of Laboratory Medicine, Asan Medical Center, University of Ulsan, College of Medicine, Seoul, South Korea
Hyun-Sook Chi
- Departments of Laboratory Medicine, Asan Medical Center, University of Ulsan, College of Medicine, Seoul, South Korea
Jung-Shin Lee
- Departments of Internal Medicine, Asan Medical Center, University of Ulsan, College of Medicine, 388-1 Pungnap-2dong, Songpa-gu, Seoul 138-736, South Korea
Woo-Kun Kim
- Departments of Internal Medicine, Asan Medical Center, University of Ulsan, College of Medicine, 388-1 Pungnap-2dong, Songpa-gu, Seoul 138-736, South Korea
Kyoo-Hyung Lee
- Departments of Internal Medicine, Asan Medical Center, University of Ulsan, College of Medicine, 388-1 Pungnap-2dong, Songpa-gu, Seoul 138-736, South Korea

Received 20 May 2005; received in revised form 20 June 2005; accepted 21 June 2005. published online 07 March 2011.

Abstract

For refractory and early relapsed AML, this prospective phase II clinical trial evaluated a salvage chemotherapy regimen, which was consisted of continuous infusion intermediate-dose cytarabine (1g/m²/day, 24h i.v. infusion×5), mitoxantrone (12mg/m²/day×3), and etoposide (150mg/m²/day×3). We treated 33 patients and 17 (51.5%) achieved CR with a median duration of 117 days. Median overall survival was 219 days. Our results suggest that continuous infusion intermediate-dose cytarabine, together with mitoxantrone and etoposide, may induce CR in a significant proportion of patients with refractory or early relapsed AML, although remission duration was short.